<DOC>
	<DOCNO>NCT00664677</DOCNO>
	<brief_summary>This study design determine safety , maximum tolerate dose , dose limit toxicity Terameprocol ( EM-1421 ) determine pharmacokinetics ( clearance blood ) Terameprocol ( EM-1421 ) give intravenous infusion three time week patient leukemia .</brief_summary>
	<brief_title>Phase 1 Study Terameprocol ( EM-1421 ) Patients With Leukemia</brief_title>
	<detailed_description>The dose Terameprocol ( EM-1421 ) escalate successive cohort 3 patient . Patients enter sequentially dose level . If none first 3 patient dose level experience first cycle drug relate dose-limiting toxicity ( DLT ) , new patient may enter next high dose level . If 1 3 patient experience first cycle DLT , 3 patient start dose level . If 2 experience first cycle DLT , patient start dose . The MTD high dose level &lt; 2 patient 6 develop first cycle DLT . New dose level may begin accrual patient current dose level observe minimum 3 week last infusion Terameprocol ( EM-1421 ) . The recommended phase 2 dose ( RP2D ) MTD unless significant clinical activity see MTD . During observation period 3 week , additional accrual previously assess low dose level , document DLTs , allow sponsor approval . Patients treat three time week , least one day infusion , two week follow one week rest . The dose new cohort escalate 1000 , 1500 2200 mg de-escalated 500 mg 1000 mg exceed MTD . The principal investigator consult sponsor determine appropriate dose level new patient . At MTD , 10 additional patient may accrue dose cohort define toxicity response agent . If initial dose level exceeds MTD , fallback dose level 500 mg implement . Patients allow treated subsequent cycle Terameprocol ( EM-1421 ) disease progression severe toxicity occur side effect outweigh benefit study drug administration assessment treat physician . Intrapatient dose escalation Intrapatient dose escalation one dose level may permit , least 3 patient next high dose level treat follow 21 day without experience DLT . Decisions intrapatient dose escalation make jointly Study Sponsor , treat physician Principal Investigator . Terameprocol ( EM-1421 ) single agent give intravenously 6 hour three time week two week follow one week rest ( two week , one week ) follow dose cohort start 1000 mg dose cohort . Dose Level -1 : 500 mg Dose Level 1 : 1000 mg Dose Level 2 : 1500 mg Dose Level 3 : 2200 mg</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Masoprocol</mesh_term>
	<criteria>1 . Patients histological confirm relapsed refractory leukemias standard therapy available expect result durable remission . Eligible patient : acute myeloid leukemia ( AML ) WHO FAB classification acute lymphocytic leukemia ( ALL ) adult T cell leukemia ( ATL ) chronic myeloid leukemia blast crisis ( CMLBP ) fail BcrAbl specific kinase inhibitor ( e.g . imatinib and/or dasatinib ) chronic lymphocytic leukemia ( CLL ) poorrisk myelodysplastic syndrome ( MDS ) [ WHO &gt; 10 % blast IPSS group : Int2 , high ] chronic myelomonocytic leukemia ( CMML ) 2 . ECOG performance status 01 3 . Negative pregnancy test within 7 day start study drug NOTE : Men woman childproducing potential must use effective contraceptive method study ( e.g . abstinence , intrauterine device [ IUD ] , oral contraceptive double barrier device ) 4 . Written inform consent 5 . In absence rapidly progress disease , interval prior therapy time study drug administration minimum 3 week cytotoxic agent least 5 halflives noncytotoxic agent . Persistent chronic toxicity prior chemotherapy must great grade 1 6 . Age great equal 18 year 7 . Patients must follow clinical laboratory value : Serum creatinine less equal 2.0 mg/dl creatinine clearance great 50ml/hr Total bilirubin less equal 1.5x upper limit normal unless consider due Gilbert 's syndrome Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3x upper limit normal unless consider due organ leukemic involvement Patients one follow criterion eligible study participation : 1 . Uncontrolled intercurrent illness include , limited , uncontrolled infection , myocardial infarction within previous 3 month , symptomatic congestive heart failure ( New York Heart Association Class III , IV ) , symptomatic coronary artery disease cardiac arrhythmia control medication NOTE : Patients control infection antibiotic antifungal therapy eligible 2 . Psychiatric illness/social situation would limit compliance study requirement unwillingness inability comply procedure require protocol 3 . Patients receive standard investigational treatment leukemia NOTE : Hydroxyurea allow prior study drug start first 7 day therapy 4 . Pregnant nursing patient exclude . NOTE : Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 5 . Major surgery , diagnostic surgery , within 4 week prior Day 1 6 . Patients know CNS disease 7 . History allergic reaction attribute compound similar chemical biological composition Terameprocol ( EM1421 ) excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Adult</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Terameprocol</keyword>
	<keyword>Survivin</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>ATL</keyword>
	<keyword>CML</keyword>
	<keyword>CLL</keyword>
	<keyword>CMML</keyword>
	<keyword>MDS</keyword>
</DOC>